4//SEC Filing
Vivo Capital Fund IX, L.P. 4
Accession 0001213900-21-034310
CIK 0001819790other
Filed
Jun 24, 8:00 PM ET
Accepted
Jun 25, 9:30 PM ET
Size
12.0 KB
Accession
0001213900-21-034310
Insider Transaction Report
Form 4
Vivo Capital IX, LLC
10% Owner
Transactions
- Sale
Common Stock
2021-06-25$29.60/sh−7,704$228,038→ 2,987,331 total(indirect: See Footnote) - Sale
Common Stock
2021-06-24$29.90/sh−10,000$299,000→ 2,995,035 total(indirect: See Footnote) - Sale
Common Stock
2021-06-23$29.80/sh−37,980$1,131,804→ 3,005,035 total(indirect: See Footnote)
Vivo Capital Fund IX, L.P.
10% Owner
Transactions
- Sale
Common Stock
2021-06-23$29.80/sh−37,980$1,131,804→ 3,005,035 total(indirect: See Footnote) - Sale
Common Stock
2021-06-24$29.90/sh−10,000$299,000→ 2,995,035 total(indirect: See Footnote) - Sale
Common Stock
2021-06-25$29.60/sh−7,704$228,038→ 2,987,331 total(indirect: See Footnote)
Footnotes (4)
- [F1]The price reported herein is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.6 to $28.3, inclusive. The reporting person undertakes to provide to Tarsus Pharmaceuticals, Inc., any security holder of Tarsus Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (1) to this Form 4.
- [F2]The price reported herein is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.2 to $29.7, inclusive. The reporting person undertakes to provide to Tarsus Pharmaceuticals, Inc., any security holder of Tarsus Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.
- [F3]The price reported herein is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.0 to $29.5, inclusive. The reporting person undertakes to provide to Tarsus Pharmaceuticals, Inc., any security holder of Tarsus Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) to this Form 4.
- [F4]The shares are held directly by Vivo Capital Fund IX, L.P. Vivo Capital IX, LLC is the general partner of Vivo Capital Fund IX, L.P. As the managing members of Vivo Capital IX, LLC, Frank Kung, Edgar Engleman, Shan Fu, Hongbo Lu, Jack Nielsen, Mahendra Shah and Michael Chang share voting and dispositive power over the shares held by Vivo Capital Fund IX, L.P., but each disclaims beneficial ownership of such shares except to the extent of their individual pecuniary interest therein.
Documents
Issuer
Tarsus Pharmaceuticals, Inc.
CIK 0001819790
Entity typeother
IncorporatedDE
Related Parties
1- filerCIK 0001750117
Filing Metadata
- Form type
- 4
- Filed
- Jun 24, 8:00 PM ET
- Accepted
- Jun 25, 9:30 PM ET
- Size
- 12.0 KB